Trial Profile
Multicentre, Open-label, Post-registration Observational Study of Elpida Used in the First Line Therapy for HIV-1 Infected Patients Against the Background of Standard Baseline ART (NNRTIs + 2 NRTIs)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Elsulfavirine (Primary) ; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms PASS
- Sponsors Viriom
- 30 Oct 2021 Results of an analysis assessing the 96- week interim efficacy and safety of Elsulfavirine presented at the 18th European AIDS Conference
- 08 Oct 2020 Results presented at the 15th International Congress on Drug Therapy and HIV Infection
- 25 Oct 2018 New trial record